Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The NIH announcement about its terminology transition and related updates was removed from the notice banner at the top of the page.
    Difference
    1%
    Check dated 2026-11-08T18:43:26.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T18:46:46.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    An NIH-wide notice about using “Super Intelligence” in place of “Artificial Intelligence” appears above the study page, which still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-25T20:29:20.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:34:31.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.0 to v3.7.1; the study record remains unavailable with a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T22:29:20.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden message with a Home button, replacing the study content with a minimal error layout and including site footer metadata.
    Difference
    20%
    Check dated 2026-09-20T20:45:38.000Z thumbnail image

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.